Methods: By using Fluorescence activated cell sorting analyse, we isolated CD90+ cells from the HCC cell lines SMCC7721 and Huh-7. And the “stemness” of CD90+ cells ware identified by sphere formation assay, colony formation assay or matrigel invasion and transwell migration assay, respectively. Immunohistochemical staining techniques was used to detect the expression levels of CD90 and CD44 in 38 hepatocellular carcinoma patients undergoing curative resection between 2008 and 2011 in our hospital. Clinicopathologic data for these patients anti-PD-1 monoclonal antibody were investigated. The prognostic
effects of CD90 and CD44 were evaluated using the wilcoxon sum rank test and compared using the log-rank test. Results: Freshly isolated CD90+ cells
were found to be more quiescent, with a greater ability to form tumors in vitro, and an ability GSK-3 inhibitor to self-renew, and metastasis. The clinical impact of CD90 was also addressed, and it was found to significantly correlate with portal vein invasion (log-rank test, p < 0.05). In another hand, CD44 were independent predictors for overall survival and disease-free survival. The expression of CD44 was associate with postoperative recurrence (log-rank test, p < 0.05), overall survival and disease-free survival rates (wilcoxon sum rank test, p < 0.01). Conclusion: CD90 and CD44 could be used as markers for human liver cancer and as potential predictors of clinical predictors of postoperative recurrence in HCC and target for the individualized therapy of this malignancy. Key Word(s): 1. HCC; 2. LCSCs; 3. CD90; 4. CD44; Presenting Author: SUN YEONG CHO Additional Authors: SEOK BAE KIM, HYUNG JUN KIM, SUNG SOO RA, YEONG KWANG CHOO, SEONG MIN JEON, HYUN DEOK SHIN, JUNG EUN SHIN, HONG JA KIM, IL HAN SONG Corresponding learn more Author: SEOK BAE KIM Affiliations: Dankook University Hospital Objective: 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography-computed
tomography) has been widely used in many kinds of malignant tumors. However, the efficacy of 18F-FDG PET-CT in hepatocellular carcinoma (HCC) is still controversy. We aimed to evaluate the usefulness of 18F-FDG PET-CT in staging and treatment of HCC. Methods: We analyzed the HCC patients retrospectively who took 18F-FDG PET-CT examination from January 2008 to December 2012. We compared the stage and treatment between before and after 18F-FDG PET-CT to know the efficacy on HCC. We reviewed the medical record, biopsy result, follow-up CT and follow-up data to know the confirmation of the extrahepatic metastasis which was suspected in 18F-FDG PET-CT. Results: Total 160 HCC patients were analyzed. 27 patients (16.9%) of them were suspected as extrahepatic metastasis on 18F-FDG PET-CT. High FDG uptake on lung was observed on 18 patients. 13 patients of them were already suspected as hematogenous lung metastasis in liver CT. 3 patients of them were diagnosed as benign lesion on chest CT and biopsy.